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Abstract 
Review on Extraskeletal myxoid chondrosarcoma, 
with data on clinics, and the genes involved. 
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Identity 
Phylum 
Soft Tissues: Tumors:Uncertain differentiation: 
Extraskeletal myxoid chondrosarcoma 
Classification 
Extraskeletal myxoid chondrosarcoma is 
characterized by a lobulated architecture (A), with a 
reticular growth pattern of interconnecting uniform 
tumor cells having ovoid-to-spindled nuclei and 
eosinophilic cytoplasm (B). 
Clinics and pathology 
Disease 
Malignant mesenchymal neoplasm of uncertain 
differentiation. 
Epidemiology 
Extraskeletal myxoid chondrosarcoma is a rare 
tumor, encompassing 2.3% of soft tissue sarcomas in 
a Japanese series. Mean ages reported in various 
series range from 46 to 57 years. Males are affected 
about twice as often as females. 
Clinics 
Location: deep soft tissues of the lower extremities 
in about 75% of the cases, especially the thigh, the 
popliteal fossa, and the buttock, and can also occur 
in the trunk, abdomen, and head and neck. 
Pathology 
 Macroscopic findings: the tumor presents as 
lobulated or multinodular mass, generally well 
circumscribed with pseudocapsule.  The size of the 
tumor at the time of diagnosis may vary from 1 to 
about 20 cm (median size 7 cm). 
 Histology: Lobulated architecture with uniform 
round to spindled cells forming interconnecting 
cords, clusters, or trabeculae in a background of 
myxoid matrix. The tumor cells have variably 
eosinophilic or vacuolated cytoplasm that extends to 
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form the reticular growth pattern. A subset of tumors 
shows hypercellularity, higher grade 
cytomorphology, and epithelioid or rhabdoid 
features. 
 A subset of tumors is positive for S100, CD117, 
synaptophysin, and neuron-specific enolase. INI1 
loss is observed in a subset, often with rhabdoid 
features. 
 Ultrastructurally, at least one third of the tumors 
demonstrate microtubular aggregates within dilated 
rough endoplasmic reticulum. 
 
Extraskeletal myxoid chondrosarcoma is characterized by a lobulated architecture (A), with a reticular growth 
pattern of interconnecting uniform tumor cells having ovoid-to-spindled nuclei and eosinophilic cytoplasm (B). 
 
Treatment 
Treatment: surgical excision, with possible adjuvant 
chemotherapy. 
Prognosis 
Prognosis: high rates of local and distant recurrence, 
including pulmonary metastasis, but with associated 
prolonged survival. 
Cytogenetics 
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NR4A3 Gene Fusions in Extraskeletal Myxoid 
Chondrosarcoma 
t(9;22)(q22;q12) EWSR1/NR4A3 
t(3;9)(q12;q22) TFG/NR4A3 
t(9;11)(q22;q24) HSPA8/NR4A3 
t(9;15)(q22;q21) TCF12/NR4A3 
t(9;16)(q22;p11) FUS/NR4A3 
t(9;17)(q22;q11) TAF15/NR4A3 
 
Left: Karyotype of extraskeletal myxoid chondrosarcoma with t(9;22)(q22;q12). Right: Fluorescence in situ 
hybridization demonstrating rearrangement of NR4A3 by break apart probe. 
 
Cytogenetics Morphological 
 Recurrent gene fusions involving 
NR4A3 on chromosome 9 are 
observed in the majority of 
extraskeletal myxoid 
chondrosarcomas. The most 
common fusion partner is 
EWSR1, resulting in 
t(9;22)(q22;q12) with fusion of 
the 5' aspect of EWSR1 with 
NR4A3. 
 Uncommon gene fusion events 
involving NR4A3 with TAF15, 
TCF12, TFG, FUS, or HSPA8 
have also been reported. These 
events result in t(9;17)(q22;q11), 
t(9;15)(q22;q21), 
t(3;9)(q12;q22), 
t(9;16)(q22;p11), or 
t(9;11)(q22;q24), respectively. 
 The breakpoint involving NR4A3 
frequently occurs in the 5' 
untranslated region, with the 
resultant fusion including the 
entire NR4A3 protein. 
 In extraskeletal myxoid 
chondrosarcomas without 
NR4A3 fusion, tumors may 
harbor loss of SMARCB1 (INI1) 
by loss of function mutation or 
gene deletion. 
 Extraskeletal myxoid 
chondrosarcomas without 
EWSR1-NR4A3 fusion may 
exhibit rhabdoid morphology and 
high grade pathological features. 
Genes involved and 
proteins 
TFG (TRK-fused gene) 
Location 
3q12.2 
DNA / RNA 
39.51 kb; 8 exons; 1.9 kb mRNA. 
Protein 
Putative signal transducer; positive regulator of I-
kappaB kinase/NF-kappaB cascade. 
NR4A3 (nuclear receptor subfamily 4, 
group A, member 3) 
Location 
9q22.33 
DNA / RNA 
Transcripts: 2.6 kb and 3.7 kb. 
Protein 
Steroid-thyroid hormone-retinoid receptor; 
transcriptional activator. 
TCF12 (transcription factor 12) 
Location 
15q21.3 
DNA / RNA 
370 kb; 21 exons; 4 kb mRNA. 
Protein 
Transcription factor; a basic helix-loop-helix 
protein. 
TAF15 (TAF15 TAF15 RNA 
polymerase II, TATA box binding 
protein (TBP)-associated factor, 
68kDa) 
Location 
17q12 
DNA / RNA 
16 exons; alternative splicing; 2.2 kb bp mRNA. 
Protein 
RNA-binding protein; part of theTFIID and RNA 
polymerase II complex. 
EWSR1 (Ewing sarcoma breakpoint 
region 1) 
Location 
22q12.2 
DNA / RNA 
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17 exons; 2.4 kb mRNA. 
Protein 
RNA-binding protein; transcription repressor. 
FUS (fusion involved in t (12;16) in 
malignant liposarcoma) 
Location 
16p11.2 
DNA / RNA 
15 exons; 1.6 kb mRNA. 
Protein 
RNA-binding protein. 
HSPA8 
Location 
11q24.1 
DNA / RNA 
9 exons; 1.9 kb mRNA. 
Protein 
Heat shock protein. 
SMARCB1 (SW1/SNF related, matrix 
associated, actin dependent 
regulator of chromatin B1) 
Location 
22q11.23 
DNA / RNA 
9 exons; 1.2 kb mRNA. 
Protein 
Core component of BAF complex. 
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